Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Marc Bonaca to Treatment Outcome

This is a "connection" page, showing publications Marc Bonaca has written about Treatment Outcome.

 
Connection Strength
  
 
 
3.294
  
  1. McDermott MM, Ho KJ, Alabi O, Criqui MH, Goodney P, Hamburg N, McNeal DM, Pollak A, Smolderen KG, Bonaca M. Disparities in Diagnosis, Treatment, and?Outcomes of Peripheral Artery?Disease: JACC Scientific Statement. J Am Coll Cardiol. 2023 12 12; 82(24):2312-2328.
    View in: PubMed
    Score: 0.086
  2. Hsia J, Spyropoulos AC, Piazza G, Weng S, Dunne MW, Lipardi C, Barnathan ES, Bonaca MP. Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials. Thromb Haemost. 2024 Jul; 124(7):649-655.
    View in: PubMed
    Score: 0.086
  3. Hess CN, Bonaca MP. Guideline-Directed Medical Therapy in?PAD: Time to Step on the Gas. JACC Cardiovasc Interv. 2023 02 13; 16(3):344-346.
    View in: PubMed
    Score: 0.081
  4. Bonaca MP, Hogan SE. Tradeoffs in Approach to PAD?Revascularization: Shared Decision Making in the Spotlight. J Am Coll Cardiol. 2023 01 31; 81(4):371-373.
    View in: PubMed
    Score: 0.081
  5. Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P, Braunwald E, Sabatine MS. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Eur Heart J. 2022 12 21; 43(48):5037-5044.
    View in: PubMed
    Score: 0.080
  6. Govsyeyev N, Nehler M, Conte MS, Debus S, Chung J, Dorigo W, Gudz I, Krievins D, Mills J, Moll F, Norgren L, Piffaretti G, Powell R, Szalay D, Sillesen H, Wohlauer M, Szarek M, Bauersachs RM, Anand SS, Patel MR, Capell WH, Jaeger N, Hess CN, Muehlhofer E, Haskell LP, Berkowitz SD, Bonaca MP. Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. J Vasc Surg. 2023 04; 77(4):1107-1118.e2.
    View in: PubMed
    Score: 0.080
  7. Hsia J, Guthrie NL, Lupinacci P, Gubbi A, Denham D, Berman MA, Bonaca MP. Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes. Diabetes Care. 2022 12 01; 45(12):2976-2981.
    View in: PubMed
    Score: 0.080
  8. Bonaca MP, Szarek M, Debus ES, Nehler MR, Patel MR, Anand SS, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. Clin Cardiol. 2022 Dec; 45(12):1143-1146.
    View in: PubMed
    Score: 0.079
  9. Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Murphy SA, Spinar J, Oude Ophuis T, Kiss RG, Lopez-Sendon J, Averkov O, Wheatcroft SB, Kubica J, Carlos Nicolau J, Furtado RHM, Abuhatzira L, Hirshberg B, Omar SA, Vavere AL, Chang YT, George RT, Sabatine MS. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B. Circulation. 2022 09 20; 146(12):907-916.
    View in: PubMed
    Score: 0.079
  10. Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MP. Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2?P-TIMI 50 trial. Clin Cardiol. 2022 Aug; 45(8):831-838.
    View in: PubMed
    Score: 0.078
  11. Szarek M, Hess C, Patel MR, Jones WS, Berger JS, Baumgartner I, Katona B, Mahaffey KW, Norgren L, Blomster J, Rockhold FW, Hsia J, Fowkes FGR, Bonaca MP. Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. J Am Heart Assoc. 2022 06 07; 11(11):e025504.
    View in: PubMed
    Score: 0.077
  12. Hogan SE, Nehler MR, Anand S, Patel MR, Debus S, Jackson MT, Buchanan C, King RW, Hess C, Muehlhofer E, Haskell LP, Bauersachs RM, Berkowitz SD, Hsia J, Bonaca MP. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med. 2022 08; 27(4):343-349.
    View in: PubMed
    Score: 0.077
  13. Hess CN, Capell WH, Bristow MR, Ruf W, Szarek M, Morrow DA, Nicolau JC, Graybill CA, Marshall D, Hsia J, Bonaca MP. Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. Am Heart J. 2022 04; 246:136-143.
    View in: PubMed
    Score: 0.075
  14. Sidhu MS, Lyubarova R, Bangalore S, Bonaca MP. Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. Am Heart J. 2022 04; 246:44-64.
    View in: PubMed
    Score: 0.075
  15. Gilchrist IC, Morrow DA, Creager MA, Olin JW, Scirica BM, Goodrich EL, Bonaca MP. Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. J Am Heart Assoc. 2021 10 19; 10(20):e021412.
    View in: PubMed
    Score: 0.074
  16. Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, ?pinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021 09 07; 10(17):e020446.
    View in: PubMed
    Score: 0.073
  17. Hess CN, Cannon CP, Beckman JA, Goodney PP, Patel MR, Hiatt WR, Mues KE, Orroth KK, Shannon E, Bonaca MP. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021 06 22; 77(24):3016-3027.
    View in: PubMed
    Score: 0.072
  18. Hess CN, Fu JW, Gundrum J, Allen LaPointe NM, Wang TY, Rogers RK, Hiatt WR, Bonaca MP. Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization. J Am Coll Cardiol. 2021 06 08; 77(22):2867-2869.
    View in: PubMed
    Score: 0.072
  19. Hsia J, Kavanagh ST, Hopley CW, Baumgartner I, Berger JS, Fowkes GR, Jones WS, Mahaffey KW, Norgren L, Patel MR, Rockhold F, Blomster J, Katona BG, Hiatt WR, Bonaca MP. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vasc Med. 2021 12; 26(6):608-612.
    View in: PubMed
    Score: 0.072
  20. Desai U, Kharat A, Hess CN, Milentijevic D, Lalibert? F, Zuckerman P, Benson J, Lefebvre P, Hiatt WR, Bonaca MP. Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Ann Vasc Surg. 2021 Aug; 75:217-226.
    View in: PubMed
    Score: 0.071
  21. Hess CN, Bonaca MP. Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circ Cardiovasc Interv. 2020 10; 13(10):e009584.
    View in: PubMed
    Score: 0.069
  22. Furtado RHM, Venkateswaran RV, Nicolau JC, Gurmu Y, Bhatt DL, Storey RF, Steg PG, Magnani G, Goto S, Dellborg M, Kamensky G, Isaza D, Aylward P, Johanson P, Bonaca MP. Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2020 05 18; 9(10):e015785.
    View in: PubMed
    Score: 0.067
  23. Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. Eur Heart J. 2020 05 01; 41(17):1625-1632.
    View in: PubMed
    Score: 0.067
  24. Bonaca MP, Hess CN, Hiatt WR. The Pathobiology of Acute Limb Ischemic?Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction. JACC Cardiovasc Interv. 2020 02 24; 13(4):428-430.
    View in: PubMed
    Score: 0.066
  25. Qamar A, Morrow DA, Creager MA, Scirica BM, Olin JW, Beckman JA, Murphy SA, Bonaca MP. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2?P-TIMI 50 trial. Vasc Med. 2020 04; 25(2):124-132.
    View in: PubMed
    Score: 0.066
  26. Govsyeyev N, Nehler MR, Hiatt WR, Bonaca MP. Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Curr Cardiol Rep. 2020 Jan 29; 22(3):13.
    View in: PubMed
    Score: 0.066
  27. Patel SM, Morrow DA, Kidd SK, Goodrich EL, Scirica BM, Bonaca MP. Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2?P-TIMI 50 trial. Vasc Med. 2019 04; 24(2):159-161.
    View in: PubMed
    Score: 0.062
  28. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 01 23; 137(4):338-350.
    View in: PubMed
    Score: 0.056
  29. Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MS. Efficacy and Safety of Ticagrelor Over?Time in Patients With Prior MI in?PEGASUS-TIMI 54. J Am Coll Cardiol. 2017 Sep 12; 70(11):1368-1375.
    View in: PubMed
    Score: 0.056
  30. Bonaca MP, Wiviott SD. Prasugrel Versus Ticagrelor: Uncertainty Remains. Circulation. 2016 11 22; 134(21):1613-1616.
    View in: PubMed
    Score: 0.053
  31. Bonaca MP, Creager MA, Olin J, Scirica BM, Gilchrist IC, Murphy SA, Goodrich EL, Braunwald E, Morrow DA. Peripheral Revascularization in Patients With?Peripheral Artery Disease With?Vorapaxar: Insights From the TRA 2?P-TIMI 50 Trial. JACC Cardiovasc Interv. 2016 10 24; 9(20):2157-2164.
    View in: PubMed
    Score: 0.052
  32. Bonaca MP. Antithrombotic Therapy in Patients With Peripheral Artery Disease. JAMA Cardiol. 2016 10 01; 1(7):803-804.
    View in: PubMed
    Score: 0.052
  33. Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2?P-TIMI 50). Circulation. 2016 Mar 08; 133(10):997-1005.
    View in: PubMed
    Score: 0.050
  34. Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, L?pez-Send?n J, Diaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MS. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 07; 37(14):1133-42.
    View in: PubMed
    Score: 0.049
  35. Magnani G, Storey RF, Steg G, Bhatt DL, Cohen M, Kuder J, Im K, Aylward P, Ardissino D, Isaza D, Parkhomenko A, Goudev AR, Dellborg M, Kontny F, Corbalan R, Medina F, Jensen EC, Held P, Braunwald E, Sabatine MS, Bonaca MP. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016 Jan 21; 37(4):400-8.
    View in: PubMed
    Score: 0.049
  36. Bonaca MP, Creager MA. Pharmacological treatment and current management of peripheral artery disease. Circ Res. 2015 Apr 24; 116(9):1579-98.
    View in: PubMed
    Score: 0.047
  37. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 ?P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2318-26.
    View in: PubMed
    Score: 0.046
  38. Bonaca MP, Murphy SA, Miller D, Herrman JP, Gottlieb S, Keltai M, Menozzi A, Nicolau JC, Widimsky P, Antman EM, Wiviott SD. Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the TIMI-38 Coronary Stent Registry. Clin Cardiol. 2014 May; 37(5):293-9.
    View in: PubMed
    Score: 0.043
  39. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013 Apr 09; 127(14):1522-9, 1529e1-6.
    View in: PubMed
    Score: 0.041
  40. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10.
    View in: PubMed
    Score: 0.035
  41. Aronow HD, Bonaca MP, Kolluri R, Beckman JA. Recapturing the Team Approach to Vascular Care. Ann Vasc Surg. 2024 Apr; 101:84-89.
    View in: PubMed
    Score: 0.021
  42. Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, Shishehbor MH, Holden AH, Bajakian DR, Garcia LA, Kum SWC, Rundback J, Armstrong E, Lee JK, Khatib Y, Weinberg I, Garcia-Garcia HM, Ruster K, Teraphongphom NT, Zheng Y, Wang J, Jones-McMeans JM, Parikh SA. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Engl J Med. 2024 Jan 04; 390(1):9-19.
    View in: PubMed
    Score: 0.021
  43. Navarese EP, Lansky AJ, Farkouh ME, Grzelakowska K, Bonaca MP, Gorog DA, Raggi P, Kelm M, Yeo B, Uminska J, Curzen N, Kubica J, Wijns W, Kereiakes DJ. Effects of Elective Coronary Revascularization vs Medical Therapy Alone on Noncardiac Mortality: A Meta-Analysis. JACC Cardiovasc Interv. 2023 05 22; 16(10):1144-1156.
    View in: PubMed
    Score: 0.021
  44. Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RF. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascul Pharmacol. 2023 04; 149:107145.
    View in: PubMed
    Score: 0.020
  45. Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 06 21; 11(12):e024655.
    View in: PubMed
    Score: 0.019
  46. Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
    View in: PubMed
    Score: 0.019
  47. Secemsky EA, Barrette E, Bockstedt L, Bonaca MP, Hess CN, Hanson T, Monteiro J, Manda B, Yeh RW. Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention. 2021 Sep 20; 17(7):590-598.
    View in: PubMed
    Score: 0.018
  48. Les?n E, Hewitt C, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Maggioni AP, Simeone JC, Ariza-Sol? A, Storey RF, Ten Berg J, Bonaca M. Extended dual antiplatelet therapy with ticagrelor 60?mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. Clin Cardiol. 2021 Oct; 44(10):1333-1343.
    View in: PubMed
    Score: 0.018
  49. Divakaran S, Carroll BJ, Chen S, Shen C, Bonaca MP, Secemsky EA. Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes. Circ Cardiovasc Qual Outcomes. 2021 08; 14(8):e007953.
    View in: PubMed
    Score: 0.018
  50. Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. Thromb Haemost. 2021 12; 121(12):1684-1695.
    View in: PubMed
    Score: 0.018
  51. Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD?Trial. J Am Coll Cardiol. 2021 07 27; 78(4):317-326.
    View in: PubMed
    Score: 0.018
  52. Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, Capell WH, Brackin T, Jaeger N, Hess CN, Pap AF, Berkowitz SD, Muehlhofer E, Haskell L, Brasil D, Madaric J, Sillesen H, Szalay D, Bauersachs R. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation. 2020 12 08; 142(23):2219-2230.
    View in: PubMed
    Score: 0.017
  53. De Luca L, Bonaca MP, Magnani G. Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review. Expert Rev Cardiovasc Ther. 2020 Dec; 18(12):881-889.
    View in: PubMed
    Score: 0.017
  54. Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MS. Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2020 05 18; 9(10):e015331.
    View in: PubMed
    Score: 0.017
  55. Sabatine MS, Hiatt WR, Goto S, Johnston SC, Bonaca MP, Steg PG, Bhatt DL, Cannon CP, Andersson M, Wallentin L. No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC Cardiovasc Interv. 2020 04 27; 13(8):1012-1014.
    View in: PubMed
    Score: 0.017
  56. Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020 05 19; 141(20):1600-1607.
    View in: PubMed
    Score: 0.017
  57. McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019 12; 7(12):899-911.
    View in: PubMed
    Score: 0.016
  58. Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MS. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019 10 01; 5(4):200-206.
    View in: PubMed
    Score: 0.016
  59. Puymirat E, Bonaca M, Iliou MC, Tea V, Ducrocq G, Douard H, Labrunee M, Plastaras P, Chevallereau P, Taldir G, Bataille V, Ferri?res J, Schiele F, Simon T, Danchin N. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. Arch Cardiovasc Dis. 2019 Aug - Sep; 112(8-9):459-468.
    View in: PubMed
    Score: 0.016
  60. Correa S, Bonaca MP, Scirica BM, Murphy SA, Goodrich EL, Morrow DA, O'Donoghue ML. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. J Thromb Thrombolysis. 2019 Apr; 47(3):353-360.
    View in: PubMed
    Score: 0.015
  61. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 05 28; 139(22):2528-2536.
    View in: PubMed
    Score: 0.015
  62. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 05 28; 139(22):2516-2527.
    View in: PubMed
    Score: 0.015
  63. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 01 15; 139(3):366-375.
    View in: PubMed
    Score: 0.015
  64. ?strand M, Amilon C, R?shammar D, Himmelmann A, Angiolillo DJ, Storey RF, Gurbel PA, Bonaca MP, Hamr?n B. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. Br J Clin Pharmacol. 2019 02; 85(2):413-421.
    View in: PubMed
    Score: 0.015
  65. Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferri?res J, Schiele F, Simon T, Danchin N, Puymirat E. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. Eur J Prev Cardiol. 2019 03; 26(4):411-419.
    View in: PubMed
    Score: 0.015
  66. Gutierrez JA, Scirica BM, Bonaca MP, Steg PG, Mosenzon O, Hirshberg B, Im K, Raz I, Braunwald E, Bhatt DL. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). Am J Cardiol. 2019 01 01; 123(1):145-152.
    View in: PubMed
    Score: 0.015
  67. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 06; 200:83-89.
    View in: PubMed
    Score: 0.014
  68. Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018 05; 199:83-91.
    View in: PubMed
    Score: 0.014
  69. Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, Armstrong EJ, Giri J, Bonaca MP, Pradhan A, Bavry AA, Kumbhani DJ. Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2017 04 10; 10(7):712-724.
    View in: PubMed
    Score: 0.014
  70. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S, James SK, Wallentin L, Clemmensen P, Roe MT, Ohman EM, Harrington RA, Mega JL, Bhatt DL, Sabatine MS, O'Donoghue ML. Potent P2Y12 Inhibitors in Men?Versus?Women: A?Collaborative?Meta-Analysis?of?Randomized?Trials. J Am Coll Cardiol. 2017 Mar 28; 69(12):1549-1559.
    View in: PubMed
    Score: 0.013
  71. Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017 05 03; 117(5):940-947.
    View in: PubMed
    Score: 0.013
  72. Kosova EC, Bonaca MP, Dellborg M, He P, Morais J, Oude Ophuis T, Scirica BM, Tendera M, Theroux P, Braunwald E, Morrow DA. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2?P-TIMI 50 trial. Eur Heart J Acute Cardiovasc Care. 2017 Mar; 6(2):164-172.
    View in: PubMed
    Score: 0.013
  73. Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DA. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation. 2016 Jul 26; 134(4):304-13.
    View in: PubMed
    Score: 0.013
  74. Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MS. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2016 Mar 15; 67(10):1145-1154.
    View in: PubMed
    Score: 0.013
  75. Berg DD, Bonaca MP, Braunwald E, Corbalan R, Goto S, Kiss RG, Murphy SA, Scirica BM, Spinar J, Morrow DA. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2?P-TIMI 50). Am J Cardiol. 2016 Apr 01; 117(7):1055-8.
    View in: PubMed
    Score: 0.012
  76. Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2?P-TIMI 50. Circulation. 2015 Nov 17; 132(20):1871-9.
    View in: PubMed
    Score: 0.012
  77. Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016 Jan 21; 37(4):390-9.
    View in: PubMed
    Score: 0.012
  78. Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KA, Murphy SA, Nicolau JC, Oude Ophuis T, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015 Mar 19; 4(3):e001505.
    View in: PubMed
    Score: 0.012
  79. Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015 Mar 24; 131(12):1047-53.
    View in: PubMed
    Score: 0.012
  80. O'Malley RG, Bonaca MP, Scirica BM, Murphy SA, Jarolim P, Sabatine MS, Braunwald E, Morrow DA. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol. 2014 Apr 29; 63(16):1644-53.
    View in: PubMed
    Score: 0.011
  81. Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar; 44(3):691-8.
    View in: PubMed
    Score: 0.010
  82. Kadakia MB, Fox CS, Scirica BM, Murphy SA, Bonaca MP, Morrow DA. Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial. Heart. 2011 Nov; 97(21):1782-7.
    View in: PubMed
    Score: 0.009
  83. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009 Sep; 158(3):335-341.e3.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)